Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (481)	1/21/2005 5:28:03 PM
From: zeta1961	Respond to of 887

Hi Tuck.. Message 20936675 This was my synopsis of the Q&A @ JPM..3/4 down the message, I wrote that they'll be presenting data at AACR that it has synergy with chemo and I do vividly remember him saying that it does not cause increased toxicity of the chemo eventhough it resensitizes and synergizes with it Perhaps Ashley who also attended will remember.. The CNBC interview(from what I recall) was more about the Iressa issue and how the stock suffered as a result and he assured the interviewer that they are fine I'd have to re-listen to the webcast to be positive..RE: ASCO, he did not volunteer it to the group..I asked him directly about it when I went to meet with him one-to-one..they are presenting.. What I got away most that was news to me, was the duration of the responses in ovarian cancer, and Telcyta's ability to resensitize chemo.. <ASCO basket>..I don't follow ARIA in depth..I probably should..the mtor inhibitors did get good coverage last year in educational seminars..I'm also trying to position for the ASCO train but I'm having trouble. Pointers welcome! Zeta Hope that helped...